Efficacy and safety of elranatamab by age and frailty in patients (pts) with relapsed/refractory multiple (RRMM): A subgroup analysis from MagnetisMM-3.

被引：0

作者：

Raje, Noopur S.

Leleu, Xavier P.

Lesokhin, Alexander M.

Mohty, Mohamad

Nooka, Ajay K.

Leip, Eric

Conte, Umberto

Viqueira, Andrea

Manier, Salomon

机构：

[1] Massachusetts Gen Hosp, Ctr Canc, Harvard Med Sch, Boston, MA USA

[2] CHU Poitiers, Hop Miletrie, Pole Reg Cancerol, Poitiers, France

[3] Mem Sloan Kettering Canc Ctr, Weill Cornell Med Coll, Div Hematol & Oncol, New York, NY USA

[4] Sorbonne Univ, Hop St Antoine, Paris, France

[5] INSERM, UMRs938, Paris, France

[6] Emory Univ Hosp, Winship Canc Inst, Atlanta, GA USA

[7] Pfizer Inc, Cambridge, MA USA

[8] Pfizer Inc, New York, NY USA

[9] Pfizer SLU, Madrid, Spain

[10] CHU Lille, Lille, France

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

8040

引用

页数：1

共 50 条

[21] MagnetisMM-3: Long-Term Update and Efficacy and Safety of Less Frequent Dosing of Elranatamab in Patients with Relapsed or Refractory Multiple Myeloma
Prince, H. Miles
Bahlis, Nizar J.
Rodriguez-Otero, Paula
Karlin, Lionel
Akard, Luke
Varshavsky-Yanovsky, Asya
Chu, Michael P.
Nagai, Yuya
Vesole, David H.
Hickman, Anne
Sullivan, Sharon T.
Leip, Eric
Conte, Umberto
Viqueira, Andrea
Lesokhin, Alexander M.
BLOOD, 2024, 144 : 4738 - 4739
[22] Carfilzomib (K) in relapsed and refractory multiple myeloma (RRMM): frailty subgroup analysis from phase 3 ASPIRE and ENDEAVOR
Facon, Thierry
Niesvizky, Ruben
Weisel, Katja
Bringhen, Sara
Ho, P. Joy
Obreja, Mihaela
Yang, Zhao
Klippel, Zandra
Blaedel, Julie
Mezzi, Khalid
Siegel, David S.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 (10): : E266 - E266
[23] Long-term survival and safety of elranatamab in patients with relapsed or refractory multiple myeloma: Update from the MagnetisMM-3 study
Tomasson, Michael H.
Iida, Shinsuke
Niesvizky, Ruben
Mohty, Mohamad
Bahlis, Nizar J.
Martinez-Lopez, Joaquin
Koehne, Guenther
Rodriguez-Otero, Paula
Prince, H. Miles
Viqueira, Andrea
Leip, Eric
Conte, Umberto
Sullivan, Sharon T.
Lesokhin, Alexander M.
HEMASPHERE, 2024, 8 (07):
[24] Carfilzomib (K) in Relapsed and Refractory Multiple Myeloma (RRMM): Frailty Subgroup Analysis from Phase 3 ASPIRE and ENDEAVOR
Facon, Thierry
Niesvizky, Ruben
Weisel, Katja
Bringhen, Sara
Ho, P. Joy
Obreja, Mihaela
Yang, Zhao
Klippel, Zandra
Blaedel, Julie
Mezzi, Khalid
Siegel, David
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 : S320 - S320
[25] Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results
Alexander M. Lesokhin
Michael H. Tomasson
Bertrand Arnulf
Nizar J. Bahlis
H. Miles Prince
Ruben Niesvizky
Paula Rodrίguez-Otero
Joaquin Martinez-Lopez
Guenther Koehne
Cyrille Touzeau
Yogesh Jethava
Hang Quach
Julien Depaus
Hisayuki Yokoyama
Afshin Eli Gabayan
Don A. Stevens
Ajay K. Nooka
Salomon Manier
Noopur Raje
Shinsuke Iida
Marc-Steffen Raab
Emma Searle
Eric Leip
Sharon T. Sullivan
Umberto Conte
Mohamed Elmeliegy
Akos Czibere
Andrea Viqueira
Mohamad Mohty
Nature Medicine, 2023, 29 : 2259 - 2267
[26] Characterization of minimal residual disease (MRD) in patients with relapsed/refractory multiple myeloma treated with elranatamab: analysis of MagnetisMM-3
Touzeau, Cyrille
Weisel, Katja
Bahlis, Nizar
Quach, Hang
Hamilton, Finn
Wang, Shen-wu
Leip, Eric
Viqueira, Andrea
O'Brien, Thomas
Rodriguez-Otero, Paula
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S82 - S83
[27] Safety and efficacy of daratumumab-based regimens in elderly (≥75 y) patients (Pts) with relapsed or refractory multiple myeloma (RRMM): Subgroup analysis of POLLUX and CASTOR.
Mateos, Maria-Victoria
Spencer, Andrew
Nooka, Ajay K.
Pour, Ludek
Weisel, Katja C.
Cavo, Michele
Laubach, Jacob
Cook, Gordon
Iida, Shinsuke
Benboubker, Lotfi
Usmani, Saad Zafar
Yoon, Sung-Soo
Bahlis, Nizar J.
Chiu, Christopher
Schecter, Jordan Mark
Wu, Kaida
Qin, Xiang
Soong, David
Dimopoulos, Meletios A.
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
[28] Efficacy and safety of Idecabtagene Vicleucel (ide-cel, bb2121) in elderly patients (Pts) with relapsed and refractory multiple myeloma (RRMM): KarMMa subgroup analysis
Einsele, H.
Berdeja, J.
Raje, N. S.
Siegel, D. S.
Lin, Y.
Anderson, L. D., Jr.
Rodriguez-Otero, P.
Manier, S.
Cavo, M.
Truppel-Hartmann, A.
Rowe, E.
Sanford, J.
Wang, J.
Campbell, T. B.
Jagannath, S.
ONCOLOGY RESEARCH AND TREATMENT, 2021, 44 : 198 - 199
[29] Efficacy and Safety of Idecabtagene vicleucel (ide-cel, bb2121) in Elderly Patients (Pts) with Relapsed and Refractory Multiple Myeloma (RRMM): KarMMa Subgroup Analysis
Einsele, Hermann
Berdeja, Jesus
Raje, Noopur
Siegel, David
Lin, Yi
Anderson, Larry, Jr.
Rodriguez-Otero, Paula
Manier, Salomon
Cavo, Michele
Truppel-Hartmann, Anna
Rowe, Everton
Sanford, Jill
Wang, Julie
Campbell, Timothy
Jagannath, Sundar
ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (SUPPL 3) : 53 - 53
[30] Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results
Lesokhin, Alexander H.
Tomasson, Michael
Arnulf, Bertrand J.
Bahlis, Nizar
Prince, H. Miles
Niesvizky, Ruben
Rodriguez-Otero, Paula
Martinez-Lopez, Joaquin
Koehne, Guenther
Touzeau, Cyrille
Jethava, Yogesh
Quach, Hang
Depaus, Julien
Yokoyama, Hisayuki
Gabayan, Afshin Eli A.
Stevens, Don K.
Nooka, Ajay
Manier, Salomon
Raje, Noopur
Iida, Shinsuke
Raab, Marc-Steffen
Searle, Emma
Leip, Eric T.
Sullivan, Sharon
Conte, Umberto
Elmeliegy, Mohamed
Czibere, Akos
Viqueira, Andrea
Mohty, Mohamad
NATURE MEDICINE, 2023, 29 (09) : 2259 - +

← 1 2 3 4 5 →